A recent study (STEP-HFpEF) found that in non-diabetic patients with obesity-related HFpEF, treatment with the GLP-1 agonist, semaglutide, resulted in significant improvements across multiple parameters [7, 190]. The gene discussed is GCG; the disease is obesity disorder.